Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug keep arthritis in remission? new study seeks answers

NCT ID NCT05622708

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 26, 2026 · Updated 25 times

Summary

This study looks at whether people with a type of spinal arthritis (non-radiographic axial spondyloarthritis) who are in remission need to keep taking the drug secukinumab to stay well. About 240 adults will either continue secukinumab or switch to a placebo to see who stays flare-free for up to 120 weeks. The goal is to find out if long-term treatment is necessary to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Bruges, 8000, Belgium

  • Novartis Investigative Site

    Genk, 3600, Belgium

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Mons, 7000, Belgium

  • Novartis Investigative Site

    Juiz de Fora, Minas Gerais, 36010 570, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90480-000, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, 14784 400, Brazil

  • Novartis Investigative Site

    Bogota, Cundinamarca, 110111, Colombia

  • Novartis Investigative Site

    Bogota, Cundinamarca, 110221, Colombia

  • Novartis Investigative Site

    Chía, Cundinamarca, 250001, Colombia

  • Novartis Investigative Site

    Bucaramanga, Santander Department, 680003, Colombia

  • Novartis Investigative Site

    Prague, 128 00, Czechia

  • Novartis Investigative Site

    Prague, 148 00, Czechia

  • Novartis Investigative Site

    Prague, 150 06, Czechia

  • Novartis Investigative Site

    Uherské Hradiště, 686 01, Czechia

  • Novartis Investigative Site

    Chambray-lès-Tours, 37170, France

  • Novartis Investigative Site

    Le Mans, 72000, France

  • Novartis Investigative Site

    Nice, 06001, France

  • Novartis Investigative Site

    Paris, 75012, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Novartis Investigative Site

    Bad Doberan, 18209, Germany

  • Novartis Investigative Site

    Berlin, 12161, Germany

  • Novartis Investigative Site

    Berlin, 13125, Germany

  • Novartis Investigative Site

    Hamburg, 22415, Germany

  • Novartis Investigative Site

    Herne, 44649, Germany

  • Novartis Investigative Site

    Ratingen, 40878, Germany

  • Novartis Investigative Site

    Székesfehérvár, Fejér, 8000, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Kistarcsa, 2143, Hungary

  • Novartis Investigative Site

    Miskolc, 3526, Hungary

  • Novartis Investigative Site

    Szeged, 6725, Hungary

  • Novartis Investigative Site

    Veszprém, 8200, Hungary

  • Novartis Investigative Site

    Kfar Saba, 4428164, Israel

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Ancona, AN, 60126, Italy

  • Novartis Investigative Site

    Torino, TO, 10128, Italy

  • Novartis Investigative Site

    Negrar, VR, 37024, Italy

  • Novartis Investigative Site

    Verona, VR, 3712, Italy

  • Novartis Investigative Site

    Kuala Lumpur, 59100, Malaysia

  • Novartis Investigative Site

    Guadalajara, Jalisco, 44650, Mexico

  • Novartis Investigative Site

    Guadalajara, Jalisco, 44690, Mexico

  • Novartis Investigative Site

    Mérida, Yucatán, 97070, Mexico

  • Novartis Investigative Site

    Chihuahua City, 31000, Mexico

  • Novartis Investigative Site

    Heerlen, Limburg, 6419 PC, Netherlands

  • Novartis Investigative Site

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Novartis Investigative Site

    Makati City, National Capital Region, 1218, Philippines

  • Novartis Investigative Site

    Manila, 1008, Philippines

  • Novartis Investigative Site

    Krakow, Lesser Poland Voivodeship, 30-727, Poland

  • Novartis Investigative Site

    Bydgoszcz, 85-168, Poland

  • Novartis Investigative Site

    Krakow, 30-002, Poland

  • Novartis Investigative Site

    Sochaczew, 96-500, Poland

  • Novartis Investigative Site

    Torun, 87-100, Poland

  • Novartis Investigative Site

    Warsaw, 02-637, Poland

  • Novartis Investigative Site

    Cluj-Napoca, Cluj, 400006, Romania

  • Novartis Investigative Site

    Bucharest, 011055, Romania

  • Novartis Investigative Site

    Bucharest, 011172, Romania

  • Novartis Investigative Site

    Bangkok, 10400, Thailand

  • Novartis Investigative Site

    Bangkok, 10700, Thailand

  • Novartis Investigative Site

    Adana, Yuregir, 01230, Turkey (Türkiye)

  • Novartis Investigative Site

    Konya, 42080, Turkey (Türkiye)

  • Novartis Investigative Site

    Ho Chi Minh City, VNM, 700000, Vietnam

  • Novartis Investigative Site

    Ho Chi Minh City, 700000, Vietnam

Conditions

Explore the condition pages connected to this study.

NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS